| Literature DB >> 32007106 |
Léo Franchetti1, Desiree M Schumann2, Michael Tamm1, Kathleen Jahn1, Daiana Stolz1.
Abstract
BACKGROUND: The identification of the pathogens in pleural effusion has mainly relied on conventional bacterial culture or single species polymerase chain reaction (PCR), both with relatively low sensitivity. We investigated the efficacy of a commercially available multiplex bacterial PCR assay developed for pneumonia to identify the pathogens involved in pleural infection, particularly empyema.Entities:
Keywords: Bacteria; Multiplex PCR; Para-pneumonic effusion; Pathogen; Pleural empyema
Mesh:
Year: 2020 PMID: 32007106 PMCID: PMC6995182 DOI: 10.1186/s12879-020-4793-6
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1Flow chart depicting patient cohort selection criteria
Basic characteristics of the study participants with pleural effusion, n = 194; cases = 214
| Missing data | ||
|---|---|---|
| Age, y | 68.8 ± 15.5 | 0 |
| Male | 112 (58) | 0 |
| unadjusted Charlson Score | 4.8 ± 2.7 | 0 |
| ASA Score | 3.1 ± 0.44 | 0 |
| Length of hospital stay, days | 16.0 (7.0;27.5) | 0 |
| Smoking status | 10 | |
| Current smoker | 42 (22) | |
| Non-smoker | 61 (31) | |
| Immune status | ||
| Immunosuppressed | 40 (18.6) | 1 |
| Signs and symptoms | 2 | |
| Cough | 91 (43) | |
| Sputum | 56 (26) | |
| Fever | 58 (27) | |
| Chest pain | 53 (25) | |
| Blood parameters | ||
| Performed | 206 (96) | 8 |
| Leucocytes (*109/l) | 10.4 ± 7.6 | 0 |
| Neutrophils (*109/l) | 7.9 ± 5.5 | 32 |
| C-reactive protein (mg/l) | 118.1 ± 109.8 | 3 |
| Lactate dehydrogenase (U/l) | 287.4 ± 208.9 | 6 |
| Pleural fluid parameters | ||
| Performed | 214 (100) | |
| Transudate | 51 (26) | 7 |
| Exudate | 146 (74) | 7 |
| Protein (g/l) | 34.2 ± 11.6 | 7 |
| Glucose (mmol/l) | 5.6 ± 2.9 | 26 |
| pH | 7.3 ± 0.23 | 35 |
| pH ≤ 7.2 | 37 (21) | 35 |
| Lactate dehydrogenase (U/l) | 1047.9 ± 3895.3 | 20 |
| Anti-infective therapy before sampling | 130 (61) | 0 |
| Antibiotics | 128 (60) | 0 |
| Anti-fungal | 11 (5) | 0 |
| Anti-viral | 10 (5) | 0 |
| Duration of antibiotic therapy | ||
| Before sampling | 1 [0;7] | 1 |
| After sampling | 8 [0;21] | 0 |
| Total | 14 [0;34] | 1 |
| Final clinical diagnosis | ||
| Empyema | 61 (29) | 0 |
| Therapeutic regime | ||
| Conservative | 175 (82) | 0 |
| Operative | 39 (18) | 0 |
| Drainage | 158 (74) | 0 |
| Medical Thoracoscopy | 83 (39) | 0 |
| Outcomes | ||
| In-house mortality within 30 days of sampling | 18 (9.3) | 0 |
| Re-hospitalisation within 90 days of discharge | 68 (35) | 0 |
| Operation within 60 days of sampling | 57 (27) | 0 |
Median (IQR) or mean (standard deviation), n (%)
Radiological investigations of the patients included in the study
| Patient number = 194; cases = 214 | |
|---|---|
| X-Ray results | |
| Performed | 128 (60) |
| Effusion | 126 (98) |
| Meniscus | 62 (48) |
| Infiltrate | 39 (30) |
| Suspicion of empyema | 4 (3) |
| CT-scan findings | |
| Performed | 139 (65) |
| Effusion | 139 (100) |
| Infiltrate | 52 (37) |
| Nodule/Tumor | 49 (35) |
| Enhancement | 20 (14) |
| Suspicion of empyema | 18 (13) |
| Ultrasound findings | |
| Performed | 189 (88) |
| Hyperechogenicity | 19 (10) |
| Septa | 42 (22) |
| Massive organisation | 35 (19) |
| single category | 73 (34) |
| Macroscopic bronchoscopy findings | |
| Performed | 73 (34) |
| No pathological finding | 24 (33) |
| Non-purulent secretion | 23 (32) |
| Erythema of the mucosa | 20 (27) |
| Purulent secretion | 17 (23) |
| Endobronchial tumour | 8 (11) |
| Bloody secretion | 5 (7) |
Pathogens and how often the pathogens were identified using conventional methods compared to the multiplex PCR-based assay
| Pathogen | Conventional method positive | Multiplex PCR-based assay positive | |
|---|---|---|---|
| 1 | Gram-negative | ||
| 1 | Gram-negative | ||
| 1 | Gram-negative | ||
| 1 | Gram-negative | ||
| 1 | 2 | Gram-positive | |
| 5 | Gram-negative | ||
| 1 | 5 | Gram-positive | |
| Pathogens not on the Curetis p55 panel | |||
| | 1 | Anaerobic | |
| | 2 | Anaerobic | |
| | 2 | Anaerobic | |
| | 1 | Gram-positive | |
| | 1 | Anaerobic | |
| | 4 | Anaerobic | |
| | 1 | Anaerobic | |
| | 1 | Gram-positive | |
| | 1 | Gram-positive | |
| | 2 | Anaerobic | |
| | 4 | Anaerobic | |
| | 1 | Anaerobic | |
| | 1 | Gram-positive | |
| | 1 | Gram-positive | |
| | 1 | Gram-positive | |
| | 5 | Anaerobic | |
| | 1 | Anaerobic | |
| | 2 | Anaerobic | |
| | 4 | Anaerobic | |
| | 1 | Anaerobic | |
| | 1 | Anaerobic | |
| | 1 | Anaerobic | |
Diagnostic performance of conventional methods and the multiplex PCR-based assay and using conventional methods, final clinical diagnosis of empyema, empyema and pleura fluid ≤7.2 as reference-standard
| 1. All cases – Conventional methods as reference-standard | Sensitivity (%) | Specificity (%) | Positive predictive value (%) |
| Multiplex PCR-based assay vs. all pathogens | 12 | 93.5 | 20 |
| Multiplex PCR-based assay vs. only panel pathogens | 67 | 93.7 | 13 |
| 2. Using cases with final clinical diagnosis of empyema - conventional methods as reference-standard | Sensitivity | Specificity | |
| Multiplex PCR-based assay vs. all pathogens | 15.8 | 80 | 27 |
| Multiplex PCR-based assay vs. only panel pathogens | 100 | 84.2 | 18 |
| 3. Using cases with or without empyema diagnosis as reference-standard | Sensitivity | Specificity | |
| Conventional methods (all pathogens) | 32.8 | 96.1 | 77 |
| Conventional methods only panel pathogens | 3.3 | 99.3 | 67 |
| Multiplex PCR-based assay | 18.6 | 97.3 | 73 |
| 4. Using cases with or without pleural fluid pH ≤ 7.2 as reference standard | Sensitivity | Specificity | |
| Conventional methods (all pathogens) | 37.8 | 95.8 | 70 |
| Conventional methods only panel pathogens | 2.7 | 99.3 | 100 |
| Multiplex PCR-based assay | 13.5 | 97.1 | 56 |
Patients with a diagnosis of no empyema compared to patients with a final diagnosis of empyema
| No Empyema | Empyema | ||
|---|---|---|---|
| Age, y | 70.4 ± 15.4 | 65.0 ± 15.2 | |
| Length of stay, days | 13 (4.0;22.0) | 25.0 (15.0;35.5) | |
| unadjusted Charlson score | 4.9 ± 2.6 | 4.7 ± 3.1 | 0.572 |
| ASA score | 3.1 ± 0.46 | 3.0 ± 0.4 | 0.668 |
| Smoking status | |||
| Current smoker | 25 (17) | 23 (38) | |
| Non-smoker | 49 (34) | 16 (27) | |
| Blood parameters | |||
| Leucocytes (*109/l) | 9.2 ± 7.4 | 13.3 ± 7.1 | |
| Neutrophils (*109/l) | 6.2 ± 3.5 | 11.3 ± 7.1 | |
| C-reactive protein (mg/l) | 81.3 ± 83.4 | 203.7 ± 116.6 | |
| Lactate dehydrogenase (U/l) | 315.8 ± 229.4 | 222.8 ± 132.6 | |
| Pleural fluid parameters | |||
| Protein (g/l) | 33.6 ± 11.3 | 36.1 ± 12.2 | 0.074 |
| Glucose (mmol/l) | 6.1 ± 2.7 | 4.3 ± 3.2 | |
| pH | 7.4 ± 0.11 | 7.1 ± 0.3 | |
| LDH (U/l) | 439.5 ± 637.5 | 3339.3 ± 7558.9 | |
| Antibiotic duration (days) | |||
| Before sampling | 0 (0;6) | 4.0 (1.0;9.0) | |
| After sampling | 5.0 (0;10) | 26.0 (15.5;37.5) | |
| Total antibiotic treatment | 7.0 (0;15) | 31.0 (20;44) | |
| Patient outcome | |||
| 30-day mortality | 12 (9) | 7 (12) | 0.598 |
Boldface p-values are significant, that is p < 0.05
Pathogens identified in multi-bacterial samples
| Pathogens | |
|---|---|
| Sample 1 | |
| Sample 2 | |
| Sample 3 | |
| Sample 4 | |
| Sample 5 | |
| Sample 6 | |
| Sample 7 | |
| Sample 8 | |
| Sample 9 |